Phase II study of low dose decitabine (5-aza-deoxycytidine) with interferon alfa-2b in advanced renal cell carcinoma.

Trial Profile

Phase II study of low dose decitabine (5-aza-deoxycytidine) with interferon alfa-2b in advanced renal cell carcinoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2011

At a glance

  • Drugs Decitabine; Interferon alpha-2b
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Jan 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 Jan 2010 Planned end date changed from 1 Oct 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top